



Emergent BioSolutions to Release Third Quarter 2009 Financial Results and Conduct a Conference Call on November 5, 2009

October 8, 2009

ROCKVILLE, Md.--(BUSINESS WIRE)--Oct. 8, 2009-- Emergent BioSolutions Inc. (NYSE:EBS) announced today it will report financial results for third quarter 2009 on Thursday, November 5, 2009, after market close.

Company management will host a conference call at 5:00 pm Eastern on November 5, 2009 to discuss the financial results for the third quarter and first nine months of 2009, recent business developments and the outlook for the remainder of 2009. The conference call will be accessible by dialing **888/680-0869** or **617/213-4854** (international) and providing passcode **12852812**. A webcast of the conference call will be accessible from the Company's website at www.emergentbiosolutions.com, under "Investors".

Emergent BioSolutions is offering call participants a pre-registration option that expedites access to the call and minimizes hold times. Pre-registrants will be issued a pin number to be used when dialing into the live call which will provide quick access to the conference call by bypassing the operator upon connection. Pre-registration, while not mandatory, can be accessed using the following website: <https://www.theconferencingservice.com/prereg/key.process?key=P38YUFUAX>

A replay of the conference call will be accessible, approximately one hour following the conclusion of the call, by dialing 888/286-8010 or 617/801-6888 and using the passcode 34130934. The replay will be available through November 19. The webcast will be archived on the company's website, www.emergentbiosolutions.com, under "Investors".

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Emergent's marketed product, BioThrax^(R) (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection. Emergent's development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia. Additional information may be found at www.emergentbiosolutions.com.

Source: Emergent BioSolutions Inc.

Emergent BioSolutions

Investors Contact:

Robert G. Burrows
Vice President, Investor Relations
301-795-1877
BurrowsR@ebsi.com

or

Media Contact:

Tracey Schmitt
Vice President, Corporate Communications
301-795-1800
SchmittT@ebsi.com